Can a higher dose of an existing eye drug cut injection frequency for wet AMD?
NCT ID NCT07728981
First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time
Summary
This trial is investigating whether a higher 8 mg dose of aflibercept, given every three months, can effectively control wet age-related macular degeneration (nAMD) in people who have not been treated before. The study will measure changes in eye fluid biomarkers, vision, and safety over 12 months. If the modified dosing works, it could mean fewer injections for patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- aflibercept 8 mg eye injection
- What this could lead to
- If successful, this dosing schedule could offer people with wet AMD a more convenient treatment option with fewer clinic visits.
- What could go wrong
- This is a small, early-phase study, so results may not apply to all patients. Higher doses may carry increased risk of eye inflammation or other side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) WET AMD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.